Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Join us as we examine key operational and clinical considerations of successful REMS programs—what makes a program work and what impact it can have. Pharmaceutical Executive Editor Joanna Breitstein sits down with Peyton Howell, president of consulting services and health policy for AmerisourceBergen Specialty Group, to address these critical issues in the first of this two-part series.
Peyton Howell
President of consulting services and health policy
AmerisourceBergen Specialty Group
Interviewer : Joanna Breitstein